J&J pauses Covid-19 vaccine trial after 'unexplained

New Post Public Reply Private Reply Replies (0) Message Board
Average_Joe
1,001
J&J pauses Covid-19 vaccine trial after 'unexplained illness'

Apologies if posted.

https://www.cnn.com/2020/10/12/health/johnson...index.html

FDA pledges Covid-19 vaccine will be guided by science 02:43
(CNN)Drugmaker Johnson & Johnson said Monday it has paused the advanced clinical trial of its experimental coronavirus vaccine because of an unexplained illness in one of the volunteers.

"Following our guidelines, the participant's illness is being reviewed and evaluated by the ENSEMBLE independent Data Safety Monitoring Board (DSMB) as well as our internal clinical and safety physicians," the company said in a statement. ENSEMBLE is the name of the study.
"Adverse events -- illnesses, accidents, etc. -- even those that are serious, are an expected part of any clinical study, especially large studies."
Most people try to avoid Covid-19. But thousands are signing up to be deliberately exposed
Most people try to avoid Covid-19. But thousands are signing up to be deliberately exposed
Johnson & Johnson's Janssen vaccine arm is developing the shot. The company did not say what the unexplained illness was, but one point of clinical trials is to find out if vaccines cause dangerous side effects. Trials are stopped when they pop up while doctors check to see if the illness can be linked to the vaccine or is a coincidence.
Content by Rosetta Stone
Learn a new language for less with these Rosetta Stone deals
Rosetta Stone has deals on one-year, two-year and even lifetime subscriptions so you can pick up a new language or two.
"Based on our strong commitment to safety, all clinical studies conducted by the Janssen Pharmaceutical Companies of Johnson & Johnson have prespecified guidelines. These ensure our studies may be paused if an unexpected serious adverse event (SAE) that might be related to a vaccine or study drug is reported, so there can be a careful review of all of the medical information before deciding whether to restart the study," the company said.
The secretive group at the center of the nation's largest vaccine trials
The secretive group at the center of the nation's largest vaccine trials
"We must respect this participant's privacy. We're also learning more about this participant's illness, and it's important to have all the facts before we share additional information," the company added.
"Serious adverse events are not uncommon in clinical trials, and the number of serious adverse events can reasonably be expected to increase in trials involving large numbers of participants. Further, as many trials are placebo-controlled, it is not always immediately apparent whether a participant received a study treatment or a placebo."
The drugmaker said there is a "significant distinction" between a study pause and a regulatory hold on a clinical trial.
Moderna chief says Covid-19 vaccine won't be widely available before late March
Moderna chief says Covid-19 vaccine won't be widely available before late March
"A study pause, in which recruitment or dosing is paused by the study sponsor, is a standard component of a clinical trial protocol," Johnson & Johnson said.
"A regulatory hold of a clinical trial is a requirement by a regulatory health authority, such as the U.S. Food and Drug Administration. As outlined in our transparency commitments, we proactively disclose any regulatory hold of a pivotal clinical trial."
Get CNN Health's weekly newsletter
Sign up here to get The Results Are In with Dr. Sanjay Gupta every Tuesday from the CNN Health team.

This is the second Phase 3 coronavirus vaccine trial to be paused in the US. AstraZeneca's vaccine trial was paused last month because of a neurological complication in a volunteer in Britain. While the trial resumed there and in other countries, it remains paused in the United States while the US Food and Drug Administration investigates.
Johnson's Phase 3 trial started in September. It's one of six coronavirus vaccines being tested in the US, and one of four in the most advanced, Phase 3 stage. It requires just one dose of vaccine, so federal officials have said they hope testing may be competed a bit faster than other vaccines, including those being made by Moderna and Pfizer, which require two doses.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Clarius Named in TIME's Top HealthTech 2026 Again

Updated Category News Views 6

When a company gets the nod from TIME two years in a row, you know they’re not just tinkering with gadgets—they’re changing the game. Clarius Mobile Health, with its cutting-edge wireless ultrasound tech, has cemented its place in TIME's World's Top HealthTech Companies of 2026. Last I checked, repeating this kind of recognition never comes easy in such a fiercely...

Continue Reading
Microplastics Webinar: Navigating Complex Regulations

Updated Category News Views 4

Buckle up, folks. The plastics debate is where regulatory battles and environmental concerns collide, and big changes are on the horizon. Let's talk about Bergeson & Campbell's latest shindig: "Plastics and Policy: Microplastics, EPR, and Other Emerging Trends"—a free-to-join webinar aiming to lift the lid on what's brewing beneath the surface of regulatory waters. The...

Continue Reading
Wrensilva Unveils Studio Console in White Oak

Updated Category News Views 4

The White Oak Revolution Out of San Diego, Wrensilva's giving audiophiles a new reason to tune in: the Studio record console now comes dressed to impress in White Oak. This marks a fresh chapter in their craftsmanship tale, marrying sleek design with the earthy charm of this beloved hardwood. And guess what? The demand for serene home listening setups is peaking like...

Continue Reading
Retirement Security Faces Global Headwinds in 2026

Updated Category News Views 10

Grappling with an Uncertain Retirement Future Welcome to the 2026 Global Retirement Index (GRI), where it seems we're all being told to brace for a rough retirement ride. This year's results, crafted by Natixis Investment Managers and their pals at CoreData Research, spotlight just how shaky the ground has gotten. The core troublemakers? Aging populations, whopping public...

Continue Reading
Miguel Pantoja: Wiring a Second Chance Beyond Bars

Updated Category News Views 5

A Second Shot with Electric Dreams Miguel Pantoja, once on the rocky road of life choices, now lights up Northern California with his spark — quite literally. Walking out of federal prison, his mind was set as firmly as a bolt: first stop was a burger, second was a plan to transform his past into a new beginning. That path took him to UEI College in Sacramento, where...

Continue Reading
Unicycive's Legal Turmoil: Opportunity for Investor Action

Updated Category News Views 4

Unicycive's Legal Headache: What's Brewing? Here we go again, folks. If you're holding shares of Unicycive Therapeutics, Inc. (UNCY), buckle up because it's looking like a storm's on the horizon. The Law Offices of Howard G. Smith have dropped the news that shareholders can step up to lead a securities fraud class action lawsuit against the company. That chance to be part...

Continue Reading
Sequel Advisors Rebrand: Founder-Centric M&A Focus

Updated Category News Views 5

What's in a Name? A Shift to Reflect Reality When a company decides it's time to shake things up with a rebrand, they better have a good reason. Enter what's now called Sequel Advisors—shedding the old label, Transact Capital, to let founders know exactly what they’re dealing with upfront. This isn't just some slick, new logo on a letterhead. It's about aligning their...

Continue Reading
BeyondCPG Accelerator Launches Seventh Growth Program

Updated Category News Views 4

Fresh Faces in Conscious Consumerism There's nothing quite like an early morning jolt of caffeine mixed with the buzz of innovation in the air. BeyondCPG, a heavyweight in the conscious products arena, has cracked open the doors to its seventh round of powerhouse brand-boosting with the launch of its new Accelerator Track 7. They're mixing heart with hustle to give...

Continue Reading
Rise Treatment Center Launches in Vegas for Teens

Updated Category News Views 5

Las Vegas Debuts Rise Adolescent Treatment Center Imagine being a parent in Las Vegas, staring at the daunting task of finding genuine help for your teenage kid just entering those rebellious years. The choices usually feel sparse and lacking. But on August 13, 2026, a shimmer of hope illuminated the landscape with the opening of Rise Adolescent Treatment Center. It’s a...

Continue Reading
Dr. David Lifschutz Honored for Psychiatry Innovation

Updated Category News Views 5

Recognizing a Legacy in Mental Wellness Under the glare of recognition's spotlight, Dr. David H. Lifschutz steps into an exclusive circle of elite professionals. He's been acknowledged as a Pinnacle Lifetime Member by The Inner Circle for his remarkable contributions to psychiatry and mental health care. This ain't just any pat on the back. It's a badge of honor stitched...

Continue Reading

Top 5 Most Recently Viewed Articles

Nano Hearing Aids' CEO Global Tour: Strengthening Connections Worldwide

Updated Category News Views 58

Nano Hearing Aids' Global Strategy: A Tour to Remember Nano Hearing Aids is taking significant strides in expanding its presence worldwide. As part of this vision, Ryan F. Zackon, the esteemed CEO, is setting out on an ambitious global tour. This initiative aims to deepen partnerships and solidify relationships within the hearing aid community. Tour Objectives: Fostering...

Continue Reading
Toll Brothers Stock: A Look at 15 Years of Growth

Updated Category News Views 141

The Impressive Journey of Toll Brothers Stock Toll Brothers (NYSE: TOL) has demonstrated remarkable resilience and growth over the past 15 years. With an average annual return of 14.07%, it has outperformed the market by 1.87%. As of now, the company's market capitalization stands at an impressive $12.22 billion. Investment Potential: What If You Bought $1,000? Imagine...

Continue Reading
DigiKey Showcases Automation Innovations at SPS 2025 Event

Updated Category News Views 198

DigiKey to Showcase Automation Innovations at SPS 2025 Global distributor highlights extensive range of industrial automation products available in Europe THIEF RIVER FALLS, Minn. — DigiKey, a renowned global distributor of electronic components and automation solutions, invites attendees of the Smart Production Solutions (SPS) conference to visit its booth, #106 in...

Continue Reading
Cocrystal Pharma Advances CDI-988 in Phase 1 Clinical Trials

Updated Category News Views 120

Exciting Progress for CDI-988 in Clinical Trials Cocrystal Pharma, Inc. (NASDAQ: COCP) recently shared encouraging findings from its Phase 1 study of CDI-988, an innovative pan-viral inhibitor, during the Military Health System Research Symposium. This multi-day event focused on advancing military medical care, with Cocrystal presenting influential data that showcases the...

Continue Reading
Increased Support for Nova Minerals' Estelle Project Advancements

Updated Category News Views 153

Introduction to the Estelle Project Nova Minerals Limited (NASDAQ: NVA) has recently reported significant support for its Estelle Gold and Critical Minerals Project from Alaska State government officials and representatives from the Australian Consulate. These interactions highlight the growing recognition of the Estelle Project as crucial for the development of both...

Continue Reading